News

Deal Announcements

Vaxart Raises Additional Venture Capital Funding

Wednesday, January 20, 2010 5:59:00 AM PDT | VentureDeal Staff
San Francisco, California  --  Pharmaceutical technology company Vaxart has garnered $3.5 million in additional venture capital investment.

Vaxart is currently testing an avian flu vaccine via the combination of adenovirus vector and adjuvant and oral administration.

Investors in the round were not disclosed, nor was how the company intends to use the financing proceeds.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1